The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Shaji KumarShaji Kumar, Mayo Clinic, Rochester, US, spoke with the Multiple Myeloma Hub about his recent paper “A simple additive staging system for newly diagnosed multiple myeloma” published in Blood Cancer Journal.
With reference to this paper, we asked, How might the MAYO Additive Staging System (MASS) score aid treatment decisions for newly diagnosed patients?
How might the MASS score aid treatment decisions for newly diagnosed patients?
Kumar begins his answer by describing the current situation regarding risk stratification in the field of multiple myeloma, including the role of the Revised International Staging System (R-ISS) and the importance of the inclusion of cytogenetic abnormalities, such chromosome 1q gain/amplification.
Kumar speaks on the creation of the MASS score using the ISS Stage III (serum β2-microglobulin ≥5.5 mg/L) and the other risk factors shown in Figure 1. Following on from this, the potential benefits of this scoring system are summarized.
Figure 1. MASS*
IGH, immunoglobulin heavy chain locus; ISS, International Staging System; LDH, lactate dehydrogenase; MASS, Mayo Additive Staging System; OS, overall survival; PFS, progression-free survival.
*Adapted from Abdallah, et al.1
References
